Skip to content

Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice

Multicenter Observational Program Evaluation of the Efficacy and Tolerability of Detralex Treatment in Patients With Chronic Venous Edema (CEAP Class С3) in Real Clinical Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03722836
Acronym
VAP-PRO-C3
Enrollment
708
Registered
2018-10-29
Start date
2018-12-06
Completion date
2019-06-20
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Venous Disease

Brief summary

The VAP-PRO-C3 is a multicenter observational program, which is carried out in the frame of routine consultations and follow-up of patients. The program includes patients with chronic venous diseases (CVDs) of CEAP class C3. It is scheduled in Russia for 2018-2019. The program is expected to enroll 90 phlebologists from 60 cities of Russia. The planned number of patients is 900

Detailed description

The study is aimed at evaluating the efficacy and safety of systemic pharmacotherapy (Detralex) as a part of combination treatment, and its influence on the general outcomes of treatment of patients with chronic venous edema (CEAP class C3) in real clinical practice. Each investigator is planned to include in the program 10 patients fulfilling the inclusion criteria. The treatment will be carried out in accordance to the routine clinical practice, instructions for the medical use of drugs, and a specific clinical situation. To assess changes in edema, the method of truncated cones and duplex ultrasound scanning (DUS) will be used.

Interventions

None listed

Sponsors

Servier Russia
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years

Inclusion criteria

* Age 18 years old or above * Written informed consent * Patient did not receive treatment with venoactive drugs within the past 4 weeks prior to the inclusion in the study * Diagnosis of chronic venous disease of class C3 (CEAP) * Decision of an attending physician to prescribe Detralex.

Exclusion criteria

* Age below 18 years old * Written informed consent is not obtained * History of alcohol or drug abuse or use of narcotic drugs * History of allergic reaction to diosmin or any other venoactive agent, or their intolerance * History of allergic reaction to anesthetics and/or sclerosing agents * Chronic venous disease of СЕАР class C0-С2 or class С4-С6 * Lymphatic edema of the lower extremities * Secondary varicose veins, angiodysplasia, or neoplasia * Arterial disease (ankle-brachial index \<0.9) * Infection within the past 6 weeks * Any of the following concomitant diseases, which can affect the results: * Connective tissue disease (including rheumatoid arthritis), arthritis * Heart failure * Intermittent claudication (peripheral artery disease) * Diseases of the bones or joints of the lower extremities * Malignancy * Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.) * History of deep vein thrombosis (within the past year) * History of superficial thrombophlebitis (within the past 3 months) * Patient cannot walk (regardless of the cause) * Obesity or body mass index \[BMI\] \>30 kg/m2 \[BMI = body mass (kg)/height (m)2\] * Predictable poor adherence to treatment * Participation of the patient in the intervention study within the previous 3 months * For women: pregnancy or breastfeeding, the desire to become pregnant within at least 2 months after the study * Patient cannot attend a follow-up visit * Patients with a contraindication to diosmin-containing agents, including Detralex

Design outcomes

Primary

MeasureTime frameDescription
Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit43 monthsVisual Analog Scale (VAS) was used in the VAP-PRO-C3 study in to discribe 5 criterions: 1.leg heaviness, 2.pain, 3. sensation of swelling, 4. night cramps 5. itching reduced from Description of the technique: It is a continuous scale in the form of a horizontal line 100 mm long with two extreme points located on it: no symptom and the strongest symptom you can imagine. The patient is asked to place a line perpendicularly crossing the visual analogue scale at the point that corresponds to his symptom intensity. The ruler measures the distance (mm) between no symptom and the strongest symptom you can imagine, providing a score range from 0 to 100. A higher score indicates a greater intensity of symptom.
Changes in the Severity of Edema, as Assessed by the Method of Truncated Cones.3 monthsTo assess changes in edema, the method of truncated cones and duplex ultrasound scanning (DUS) will be used. The method is based on the assumption that the shape of the lower extremity approaches the shape of several truncated cones connected by bases that coincide in area. The volume of the cone is calculated by measuring the circumference of the upper (C) and lower (c) cones and the height (h) between them. For calculating the volume of each cone, the following formula is used: V = (p / 12p) ² h (C² + Cc + c²), The volume of the lower limb is determined by summing the volumes of all the cones. The smaller the height of the segments, the more accurate the result.

Secondary

MeasureTime frameDescription
Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit43 monthChronic Venous Insufficiency Questionnaire (CIVIQ-14) is a specific questionnaire for venous disease. It was used to describe the patients quality of life. Questionnaire consists of 3 dimenions: 1. pain in ankles or legs 2. scale of physical condition 3.influence to psychological state It is a SELF-reported survey where each patient has to circle the number (from 1 to 5): of which 1 means NO signs or symptons (the best result) and 5 stands for the worst state CIVIQ 14 consists of 14 questions, each question has a maximum score of 5 points. So 70 points indicates maximum reduced QoL, and 14 - best state of QoL. In order to compare the mean scores between dimensions, absolute scores were converted into an index. For each dimension, we obtained a result ranging from 0 to 100. Interpretation: the highest figure can be allocated to the lowest response option and vice versa.

Countries

Russia

Participant flow

Participants by arm

ArmCount
Patients With CVD of CEAP Class C3
the patients could receive any type of treatment for CVD
708
Total708

Baseline characteristics

CharacteristicPatients With CVD of CEAP Class C3
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
181 Participants
Age, Categorical
Between 18 and 65 years
527 Participants
Age, Continuous48.6 years
STANDARD_DEVIATION 12.6
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Russia
708 participants
Sex: Female, Male
Female
532 Participants
Sex: Female, Male
Male
176 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 708
other
Total, other adverse events
0 / 708
serious
Total, serious adverse events
0 / 708

Outcome results

Primary

Changes in the Severity of Edema, as Assessed by the Method of Truncated Cones.

To assess changes in edema, the method of truncated cones and duplex ultrasound scanning (DUS) will be used. The method is based on the assumption that the shape of the lower extremity approaches the shape of several truncated cones connected by bases that coincide in area. The volume of the cone is calculated by measuring the circumference of the upper (C) and lower (c) cones and the height (h) between them. For calculating the volume of each cone, the following formula is used: V = (p / 12p) ² h (C² + Cc + c²), The volume of the lower limb is determined by summing the volumes of all the cones. The smaller the height of the segments, the more accurate the result.

Time frame: 3 months

ArmMeasureValue (MEAN)Dispersion
Patients With CVD of CEAP Class C3Changes in the Severity of Edema, as Assessed by the Method of Truncated Cones.289 mLStandard Deviation 234
Primary

Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4

Visual Analog Scale (VAS) was used in the VAP-PRO-C3 study in to discribe 5 criterions: 1.leg heaviness, 2.pain, 3. sensation of swelling, 4. night cramps 5. itching reduced from Description of the technique: It is a continuous scale in the form of a horizontal line 100 mm long with two extreme points located on it: no symptom and the strongest symptom you can imagine. The patient is asked to place a line perpendicularly crossing the visual analogue scale at the point that corresponds to his symptom intensity. The ruler measures the distance (mm) between no symptom and the strongest symptom you can imagine, providing a score range from 0 to 100. A higher score indicates a greater intensity of symptom.

Time frame: 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4leg heaviness- Visit 053.8 mmStandard Deviation 21.9
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4leg heaviness- Visit 415.6 mmStandard Deviation 15.6
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4pain- Visit 042.4 mmStandard Deviation 23.9
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4pain- Visit 411.2 mmStandard Deviation 13.7
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4sensation of swelling - Visit 056.8 mmStandard Deviation 24.4
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4sensation of swelling - Visit 413.8 mmStandard Deviation 15.9
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4night cramps -Visit 024.6 mmStandard Deviation 23.3
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4night cramps -Visit 45.8 mmStandard Deviation 12
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4itching -Visit 014.6 mmStandard Deviation 20.6
Patients With CVD of CEAP Class C3Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4itching -Visit 44.3 mmStandard Deviation 10.1
Secondary

Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4

Chronic Venous Insufficiency Questionnaire (CIVIQ-14) is a specific questionnaire for venous disease. It was used to describe the patients quality of life. Questionnaire consists of 3 dimenions: 1. pain in ankles or legs 2. scale of physical condition 3.influence to psychological state It is a SELF-reported survey where each patient has to circle the number (from 1 to 5): of which 1 means NO signs or symptons (the best result) and 5 stands for the worst state CIVIQ 14 consists of 14 questions, each question has a maximum score of 5 points. So 70 points indicates maximum reduced QoL, and 14 - best state of QoL. In order to compare the mean scores between dimensions, absolute scores were converted into an index. For each dimension, we obtained a result ranging from 0 to 100. Interpretation: the highest figure can be allocated to the lowest response option and vice versa.

Time frame: 3 month

ArmMeasureGroupValue (MEAN)Dispersion
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4psychological state scale -Visit 45.7 mean for index valuesStandard Deviation 9
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4pain scale - Visit 041.0 mean for index valuesStandard Deviation 19.1
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4pain scale - Visit 412.8 mean for index valuesStandard Deviation 11.6
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4scale of physical condition -Visit 031.6 mean for index valuesStandard Deviation 23.8
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4scale of physical condition -Visit 411.1 mean for index valuesStandard Deviation 15.4
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4psychological state scale -Visit 024.5 mean for index valuesStandard Deviation 21.1
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4Global index score - Visit 032.4 mean for index valuesStandard Deviation 18.5
Patients With CVD of CEAP Class C3Patients' Quality of Life According to CIVIQ-14 - Visit 0 vs Visit4Global index score - Visit 49.9 mean for index valuesStandard Deviation 9.9

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026